Skip to main
Wolverine MD

A deep-space research console on the Wolverine blend — BPC-157 and TB-500 tracked as two tissue-repair channels, with the animal tendon and ligament evidence, the human-data gaps, and the regulatory access record surfaced as system status.

Studies and FDA pages used here

How do you check the BPC-157 TB-500 references?

Each number and claim about a study leads to its source. Below, you can open a study or FDA page and read the words for yourself.

Return to the findingsRead the tendon work

How can you use this source list?

How can you trace a claim back to its source? The numbered list below gives you a study link or an FDA page for every claim.

The older studies near the top are where the rat results come from: tendons and ligaments that healed stronger, new blood vessels, faster-moving cells, and how chemists first made TB-500. Below them sit the reviews and rat studies from 2025-2026, which found the human evidence thin.

Near the end come the FDA pages about when a pharmacy may make a drug from a raw ingredient. I’d open those first if a clinic makes a claim about today’s legal rules.

Keep one warning in mind while reading the TB-500 studies. Most studies on repair examined the full Thymosin Beta-4 protein, not the far shorter form sold in a vial [4][9].

That difference may change what the finding means for your own care. The list below gives the full name and link for each study.

  1. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
  2. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. ↗
  3. Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004;23(18):3599-3608. ↗
  4. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. ↗
  5. Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. ↗
  6. Cerovecki T, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155-1161. ↗
  7. Krivic A, et al. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006;24(5):982-989. ↗
  8. Staresinic M, et al. Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disabled Myotendinous Junctions in Rats. Biomedicines. 2021;9(11):1547. ↗
  9. Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. ↗
  10. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. ↗
  11. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. ↗
  12. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
  13. Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats. Pharmaceutics. 2025;17(1):119. ↗
  14. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. (List entries for BPC-157 and for 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500' effective with the September 29, 2023 update.) ↗
  15. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. (Definitions of Category 1 and Category 2; the January 7, 2025 revised interim policy on newly nominated substances.) ↗
  16. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. (Public calendar listing BPC-157, KPV, TB-500, and MOTs-C as substances being considered for inclusion on the 503A Bulks List.) ↗
  17. Cha HJ, Jeong MJ, Kleinman HK. Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst. 2003. ↗
  18. Ho ENM, et al.. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012. ↗
  19. Ruff D, et al.. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010. ↗
  20. et al.. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers. J Cell Mol Med. 2021. ↗